Mitochondrial Disease in Childhood: Nuclear Encoded

Neurotherapeutics

Volumn 10, Issue 2, 2013, Pages 212-226

  Goldstein, Amy C ^a   Bhatia, Poonam ^a   Vento, Jodie M ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Alpers syndrome; Developmental regression; Encephalomyopathy; Leigh syndrome; Mitochondrial; POLG

Indexed keywords

ADENOSINE TRIPHOSPHATE; MITOCHONDRIAL DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE;

ALPERS DISEASE; ATAXIA; AUTOSOMAL RECESSIVE DISORDER; AWARENESS; CEREBROVASCULAR ACCIDENT; CHILDHOOD DISEASE; CHILDHOOD MYOCEREBROHEPATOPATHY; DISEASE CLASSIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENCEPHALOMYOPATHY; ENDOCRINE DISEASE; EPILEPSY; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LEIGH DISEASE; LIVER DISEASE; MNGIE SYNDROME; MYOCLONUS EPILEPSY; NEUROPATHY; OXIDATIVE PHOSPHORYLATION; PERCEPTION DEAFNESS; PHENOTYPE; PHYSICIAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW;

EID: 84876163198     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0185-6     Document Type: Review

References (144)

1. Shoffner J. Oxidative phosphorylation disease diagnosis. Semin Neurol 1999; 19: 341-351.
2. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003; 348: 2656-2668.
3. Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003; 126: 1905-1912.
4. Wang Y, Mohsen AW, Mihalik SJ, Goetzman ES, Vockley J. Evidence for physical association of mitochondrial fatty acid oxidation and oxidative phosphorylation complexes. J Biol Chem 2010; 285: 29834-298341.
5. Haack TB, Danhauser K, Haberberger B, Hoser J, Strecker V, Boehm D, et al. Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet 2010; 42: 1131-1134.
6. Enns GM, Bennett MJ, Hoppel CL, Goodman SI, Weisiger K, Ohnstad C, et al. Mitochondrial respiratory chain complex I deficiency with clinical and biochemical features of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. J Pediatr 2000; 136: 251-254.
7. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell 2008; 134: 112-123.
8. Thorburn DR. Mitochondrial disorders: prevalence, myths and advances. J Inherit Metab Dis 2004; 27: 349-362.
9. DiMauro S, Davidzon G. Mitochondrial DNA and disease. Ann Med 2005; 37: 222-232.
10. Kirby DM, Thorburn DR. Approaches to finding the molecular basis of mitochondrial oxidative phosphorylation disorders. Twin Res Hum Genet 2008; 11: 395-411.
11. Scaglia F, Towbin JA, Craigen WJ, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 2004; 114: 925-931.
12. Koopman WJ, Willems PH, Smeitink JA: Monogenic mitochondrial disorders. N Engl J Med 2012; 366: 1132-1141.
13. Zhu X, Peng X, Guan MX, Yan Q. Pathogenic mutations of nuclear genes associated with mitochondrial disorders. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 179-187.
14. DiMauro S, Schon EA: Mitochondrial disorders in the nervous system. Annu Rev Neurosci 2008; 31: 91-123.
15. Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, Tucker, EJ, et al. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med 2012; 4: 118ra10.
16. Haas R, Parikh S, Falk M, Saneto R, Wolf N, Darin N, et al. The in-depth evaluation of suspected mitochondrial disease: The Mitochondrial Medicine Society's Committee on Diagnosis. Mol Genet Metab 2008; 94: 16-37.
17. Leonard JV, Schapira AH. Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet 2000; 355: 389-394.
18. DiMauro S, Davidzon G. Mitochondrial DNA and disease. Ann Med 2005; 37: 222-232.
19. Thorburn DR, Sugiana C, Salemi R, Kirby DM, Worgan L, Ohtake A, et al. Biochemical and molecular diagnosis of mitochondrial respiratory chain disorders. Biochim Biophys Acta 2004; 1659: 121-128.
20. Haas R, Parikh S, Falk M, Saneto RP, Wolf NI, Darin N, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 2007; 120: 1326-1333.
21. Rahman S. Mitochondrial disease and epilepsy. Dev Med Child Neurol 2012; 54: 397-406.
22. Calvo SE, Mootha VK. The mitochondrial proteome and human disease. Annu Rev Genomics Hum Genet 2010; 11: 25-44.
23. McFarland R, Kirby DM, Fowler KJ, Ohtake A, Ryan MT, Amor DJ, et al. De novo mutations in the mitochondrial ND3 gene as a cause of infantile mitochondrial encephalopathy and complex I deficiency. Ann Neurol 2004; 55: 58-64.
24. Triepels RH, van den Heuvel LP, Trijbels JM, Smeitink JA. Respiratory chain complex I deficiency. Am J Med Genet 2001; 106: 37-45.
25. DiMauro S, Hirano M. Mitochondrial encephalomyopathies: an update. Neuromuscul Disord 2005; 15: 276-286.
26. Martin MA, Blazquez A, Gutierrez-Solana LG, Fernandez-Moreira D, Briones P, Andreu AL, et al. Leigh syndrome associated with mitochondrial complex I deficiency due to a novel mutation in the NDUFS1 gene. Arch Neurol 2005; 62: 659-661.
27. Loeffen JL, Smeitink JA, Trijbels JM, Janssen AJ, Triepels RH, Sengers RC, et al. Isolated complex I deficiency in children: clinical, biochemical and genetic aspects. Hum Mutat 2000; 15: 123-134.
28. Pitkanen S, Feigenbaum A, Laframboise R, Robinson BH. NADH-coenzyme Q reductase (complex I) deficiency: heterogeneity in phenotype and biochemical findings. J Inherit Metab Dis 1996; 19: 675-686.
29. Lebre AS, Rio M, Faivre d'Arcier L, Vernerey D, Landrieu P, Slama A, et al. A common pattern of brain MRI imaging in mitochondrial diseases with complex I deficiency. J Med Genet 2011; 48: 16-23.
30. Ogilvie I, Kennaway NG, Shoubridge EA. A molecular chaperone for mitochondrial complex I assembly is mutated in a progressive encephalopathy. J Clin Invest 2005; 115: 2784-2792.
31. Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Péquignot E, et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet 1995; 2: 144-149.
32. Riggs JE, Schochet SS, Jr, Fakadej AV, Papadimitriou A, DiMauro S, Crosby TW, et al. Mitochondrial encephalomyopathy with decreased succinate-cytochrome-c-reductase activity. Neurology 1984; 34: 48-53.
33. Reichmann H, Angelini C. Single muscle fibre analyses in 2 brothers with succinate dehydrogenase deficiency. Eur Neurol 1994; 34: 95-98.
34. Bourgeois M, Goutieres F, Chretien D, Rustin P, Munnich A, Aicardi J. Deficiency in complex II of the respiratory chain, presenting as a leukodystrophy in two sisters with Leigh syndrome. Brain Dev 1992; 14: 404-408.
35. Ghezzi D, Goffrini P, Uziel G, Horvath R, Klopstock T, Lochmüller H, et al. SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy. Nat Genet 2009; 654-656.
36. Ghezzi D, Arzuffi P, Zordan M, Da Re C, Lamperti C, Benna C, et al. Mutations in TTC19 cause mitochondrial complex III deficiency and neurological impairment in humans and flies. Nature Genet 2011; 43: 259-263.
37. Haut S, Brivet M, Touati G, Rustin P, Lebon S, Garcia-Cazorla A, et al. A deletion in the human QP-C gene causes a complex III deficiency resulting in hypoglycaemia and lactic acidosis. Hum Genet 2003; 113: 118-122.
38. Barel O, Shorer Z, Flusser H, Ofir R, Narkis G, Finer G, et al. Mitochondrial complex III deficiency associated with a homozygous mutation in UQCRQ. Am J Hum Genet 2008; 82: 1211-1216.
39. de Lonlay P, Valnot I, Barrientos A, Gorbatyuk M, Tzagoloff A, Taanman JW, et al. A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure. Nature Genet 2001; 29: 57-60.
40. Visapää I, Fellman V, Vesa J, Dasvarma A, Hutton JL, Kumar V, et al. GRACILE syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L. Am J Hum Genet 2002; 71: 863-876.
41. De Meirleir L, Seneca S, Damis E, Sepulchre B, Hoorens A, Gerlo E, et al. Clinical and diagnostic characteristics of complex III deficiency due to mutations in the BCS1L gene. Am J Med Genet A 2003; 121A: 126-131.
42. Hinson JT, Fantin VR, Schönberger J, Breivik N, Siem G, McDonough B, et al. Missense mutations in the BCS1L gene as a cause of the Björnstad syndrome. N Engl J Med 2007; 356: 809-819.
43. Shoubridge EA. Cytochrome c oxidase deficiency. Am J Med Genet 2001; 106: 46-52.
44. Massa V, Fernandez-Vizarra E, Alshahwan S, Bakhsh E, Goffrini P, Ferrero I, et al. Severe infantile encephalomyopathy caused by a mutation in COX6B1, a nucleus-encoded subunit of cytochrome c oxidase. Am J Hum Genet 2008; 82: 1281-1289.
45. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A 1989; 86: 2379-2382.
46. Qunzii C, Hirano M. Primary and secondary CoQ10 deficiencies in humans. Biofactors 2011; 37: 361-365.
47. van Maldergem L, Trijbels F, DiMauro S, Sindelar PJ, Musumeci O, Janssen A, et al. Coenzyme Q-responsive Leigh's encephalopathy in two sisters. Ann Neurol 2002; 52: 750-754.
48. Moraes CT, Shanske S, Tritschler HJ, Aprille JR, Andreetta F, Bonilla E, et al. mtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet 1991; 483: 492-501.
49. Vu TH, Sciacco M, Tanji K, Nichter C, Bonilla E, Chatkupt S, et al. Clinical manifestations of mitochondrial DNA depletion. Neurology 1998; 50: 1783-1790.
50. Spinazzola A, Zeviani M. Disorders of nuclear-mitochondrial intergenomic signaling. Gene 2005; 354: 162-168.
51. van Goethem G. Autosomal disorders of mitochondrial DNA maintenance. Acta Neurol Belg 2006; 106: 66-72.
52. Sarzi E, Bourdon A, Chrétien D, Zarhrate M, Corcos J, Slama A, et al. Mitochondrial DNA depletion is a prevalent cause of multiple respiratory chain deficiency in childhood. J Pediatr 2007; 150: 531-534.
53. Copeland WC. Inherited mitochondrial diseases of DNA replication. Annu Rev Med 2008; 59: 131-146.
54. Suomalainen A, Isohanni P. Mitochondrial DNA depletion syndromes-many genes, common mechanisms. Neuromuscul Disord 2010; 20: 429-437.
55. Kaguni LS. DNA polymerase gamma, the mitochondrial replicase. Annu Rev Biochem 2004; 73: 293-320.
56. Cohen BH, Naviaux RK. The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. Methods 2010; 51: 364-373.
57. Human DNA Polymerase Gamma Mutation Database. Available at: http://tools. niehs. nih. gov/polg/. Accessed July 15, 2012.
58. Tang S, Wang J, Lee NC, Milone M, Halberg MC, Schmitt ES, et al. Mitochondrial DNA polymerase gamma mutations: an ever expanding molecular and clinical spectrum. J Med Genet 2011; 48: 669-681.
59. Naviaux RK, Nguyen KV. POLG mutations associated with Alpers syndrome and mitochondrial DNA depletion. Ann Neurol 2005; 58: 491.
60. Nguyen KV, Sharief FS, Chan SS, Copeland WC, Naviaux RK. Molecular diagnosis of Alpers syndrome. J Hepatol 2006; 45: 108-116.
61. Saneto RP, Lee IC, Koenig MK, Bao X, Weng SW, Naviaux RK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 2010; 19: 140-146.
62. Bicknese AR, May W, Hickey WF, Dodson WE. Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. Ann Neurol 1992; 32: 767-775.
63. Horvath R, Hudson G, Ferrari G. Phenotypic spectrum associated with mutations of the mitochondrial polymerase γ gene. Brain 2006; 129: 1674-1684.
64. van Goethem G, Mercelis R, Löfgren A, Seneca S, Ceuterick C, Martin JJ, et al. Patient homozygous for a recessive POLG mutation presents with features of MERRF. Neurology 2003; 61: 1811-1813.
65. van Goethem G, Luoma P, Rantamäki M, Al Memar A, Kaakkola S, Hackman P, et al. POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology 2004; 63: 1251-1257.
66. Fadic R, Russell JA, Vedanarayanan VV, Lehar M, Kuncl RW, Johns DR. Sensory ataxic neuropathy as the presenting feature of a novel mitochondrial disease. Neurology 1997; 49: 239-245.
67. Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 2008; 10150-10172.
68. Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain 2011; 134: 3326-3332.
69. Nogueira C, Carrozzo R, Vilarinho L, Santorelli FM. Infantile-onset disorders of mitochondrial replication and protein synthesis. J Child Neurol 2011; 26: 866-875.
70. Kemp JP, Smith PM, Pyle A, Neeve VC, Tuppen HA, Schara U, et al. Nuclear factors involved in mito translation cause a subgroup of combined RC deficiency. Brain 2011; 134: 183-195.
71. Miller C, Saada A, Shaul N, Shabtai N, Ben-Shalom E, Shaag A, et al. Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation. Ann Neurol 2004; 56: 734-738.
72. Scheper GC, van der Klok T, van Andel RJ, van Berkel CG, Sissler M, Smet J, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet 2007; 39: 534-539.
73. Edvardson S, Shaag A, Kolesnikova O, Gomori JM, Tarassov I, Einbinder T, et al. Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. Am J Hum Genet 2007; 81: 857-862.
74. Cassandrini D, Cilio MR, Bianchi M, Doimo M, Balestri M, Tessa A, et al. Pontocerebellar hypoplasia type 6 caused by mutations in RARS2: definition of the clinical spectrum and molecular findings in five patients. J Inherit Metab Dis. 2012 May 8 [Epub ahead of print].
75. Jordanova A, Irobi J, Thomas FP, van Dijck P, Meerschaert K, Dewil M, et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet 2006; 38: 197-202.
76. Fichera M, Lo Giudice M, Falco M, Sturnio M, Amata S, Calabrese O, et al. Evidence of kinesin heavy chain (KIF5A) involvement in pure hereditary spastic paraplegia. Neurology 2004; 63: 1108-1110.
77. Amati-Bonneau P, Milea D, Bonneau D, Chevrollier A, Ferré M, Guillet V, et al. OPA1-associated disorders: phenotypes and pathophysiology. Int J Biochem Cell Biol 2009; 41: 1855-1865.
78. Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36: 449-451.
79. Barth PG, Valianpour F, Bowen VM, Lam J, Duran M, Vaz FM, et al. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am J Med Genet A 2004; 126: 349-354.
80. Wortmann SB, Vaz FM, Gardeitchik T, Vissers LE, Renkema GH, Schuurs-Hoeijmakers JH, et al. Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness. Nat Genet 2012; 44: 797-802.
81. Mayr JA, Haack TB, Graf E, Zimmermann FA, Wieland T, Haberberger B, et al. Lack of the mitochondrial protein acylglycerol kinase causes Sengers syndrome. Am J Hum Genet 2012; 90: 314-320.
82. Palmieri F, Pierri CL. Mitochondrial metabolite transport. Essays Biochem 2010; 47: 37-52.
83. Palmieri F. Diseases caused by defects of mitochondrial carriers: a review. Biochim Biophys Acta 2008; 1777: 564-578.
84. Roesch K, Curran SP, Tranebjaerg L, Koehler CM. Human deafness dystonia syndrome is caused by a defect in assembly of the DDP1/TIMM8a-TIMM13 complex. Hum Mol Genet 2002; 11: 477-486.
85. Munnich A, Rotig A, Chretien D, Cormier V, Bourgeron T, Bonnefont JP, et al. Clinical presentation of mitochondrial disorders in childhood. J Inherit Metab Dis 1996; 19: 521-527.
86. Johns DR. Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. N Engl J Med 1995; 333: 638-644.
87. Parikh S. The neurologic manifestations of mitochondrial disease. Dev Disabil Res Rev 2010; 16: 120-128.
88. Deschauer M, Tennant S, Rokicka A, He L, Kraya T, Turnbull DM, et al. MELAS associated with mutations in the POLG1 gene. Neurology 2007; 68: 1741-1742.
89. Ito H, Mori K, Kagami S. Neuroimaging of stroke-like episodes in MELAS. Brain Dev 2011; 33: 283-288.
90. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry 1951; 14: 216-221.
91. Finsterer J, Kopsa W. Basal ganglia calcification in mitochondrial disorders. Metab Brain Dis 2005; 20: 219-226.
92. Farina L, Chiapparini L, Uziel G, Bugiani M, Zeviani M, Savoiardo M. MR findings in Leigh syndrome with COX deficiency and SURF-1 mutations. Am J Neuroradiol 2002; 23: 1095-1100.
93. Finsterer J. Leigh and Leigh-Like syndrome in children and adults. Pediatr Neurol 2008; 39: 223-235.
94. Willis TA, Davidson J, Gray RG, Poulton K, Ramani P, Whitehouse W. Cytochrome oxidase deficiency presenting as birth asphyxia. Dev Med Child Neurol 2000; 42: 414-417.
95. Wick R, Scott G, Byard RW. Mechanisms of unexplained death and autopsy findings in Leigh syndrome (subacute necrotizing encephalomyelopathy). J Forensic Leg Med 2007; 14: 42-45.
96. Sakushima K, Tsuji-Akimoto S, Niino M, Saitoh S, Yabe I, Sasaki H. Adult Leigh disease without failure to thrive. Neurologist 2011; 17: 222-227.
97. Loeffen J, Smeitink J, Triepels R, Smeets R, Schuelke M, Sengers R, et al. The first nuclear-encoded complex I mutation in a patient with Leigh syndrome. Am J Hum Genet 1998; 63: 1598-1608.
98. Rahman S, Blok RB, Dahl HH, Danks DM, Kirby DM, Chow CW, et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol 1996; 39: 343-351.
99. Tiranti V, Hoertnagel K, Carrozzo R, Galimberti C, Munaro M, Granatiero M, et al. Mutations of SURF-1 in Leigh disease associated with cytochrome c oxidase deficiency. Am J Hum Genet 1998; 63: 1609-1621.
100. Dahl H. Getting to the nucleus of mitochondrial disorders: identification of respiratory chain-enzyme genes causing Leigh syndrome. Am J Hum Genet 1998; 63: 1594-1597.
101. López LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, Naini A, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006; 79: 1125-1129.
102. Dimmock DP, Zhang Q, Dionisi-Vici C, Carrozzo R, Shieh J, Tang LY, et al. Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase. Hum Mutat 2008; 29: 330-331.
103. Spinazzola A, Invernizzi F, Carrara F, Lamantea E, Donati A, Dirocco M, et al. Clinical and molecular features of mitochondrial DNA depletion syndromes. J Inherit Metab Dis 2009; 32: 143-158.
104. Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001; 29: 337-341.
105. Finsterer J. Mitochondrial disorders, cognitive impairment and dementia. J Neurol Sci 2009; 283: 143-148.
106. Finsterer J. Cognitive dysfunction in mitochondrial disorders. Acta Neurol Scand 2012; 126: 1-11.
107. Finsterer J. Cognitive decline as a manifestation of mitochondrial disorders (mitochondrial dementia). J Neurol Sci 2008; 272: 20-33.
108. Parikh S, Cohen BH, Gupta A, Lachhwani DK, Wyllie E, Kotagal P. Metabolic testing in the pediatric epilepsy unit. Pediatr Neurol 2008; 38: 191-195.
109. Lee YM, Kang HC, Lee JS, Kim SH, Kim EY, Lee SK, et al. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia 2008; 49: 685-690.
110. El Sabbagh S, Lebre AS, Bahi-Buisson N, Delonlay P, Soufflet C, Boddaert N, et al. Epileptic phenotypes in children with respiratory chain disorders. Epilepsia 2010; 51: 1225-1235.
111. Molinari F, Raas-Rothschild A, Rio M, Fiermonte G, Encha-Razavi F, Palmieri L, et al. Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet 2005; 76: 334-339.
112. Joshi CN, Greenberg CR, Mhanni AA, Salman MS. Ketogenic diet in Alpers-Huttenlocher syndrome. Pediatr Neurol 2009; 40: 314-316.
113. Kang HC, Lee YM, Kim HD, Lee JS, Slama A. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007; 48: 82-88.
114. Kossoff EH, Zupec-Kania BA, Amark PE, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009; 50: 304-317.
115. Nangia S, Caraballo RH, Kang HC, Nordli DR, Scheffer IE. Is the ketogenic diet effective in specific epilepsy syndromes? Epilepsy Res 2012; 100: 252-257.
116. DeVivo DC, Haymond MW, Leckie MP, Bussman YL, McDougal DB, Jr, Pagliara AS. The clinical and biochemical implications of pyruvate carboxylase deficiency. J Clin Endocrinol Metab 1997; 45: 1281-1296.
117. Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010; 52: 1791-1796.
118. Poretti A, Wolf NI, Boltshauser E. Differential diagnosis of cerebellar atrophy in childhood. Eur J Paediatr Neurol 2008; 12: 155-167.
119. Finsterer J. Mitochondrial ataxias. Can J Neurol Sci 2009; 36: 543-553.
120. Delatycki MB, Williamson R, Forrest SM. Friedreich ataxia: an overview. J Med Genet 2000; 37: 1-8.
121. Newman NJ. Mitochondrial disease and the eye. Ophthalmol Clin North Am 1992; 5: 405-424.
122. Mullie MA, Harding AE, Petty RK, Ikeda H, Morgan-Hughes JA, Sanders MD. The retinal manifestations of mitochondrial myopathy. Arch Opthalmol 1985; 103: 1825-1830.
123. Grönlund MA, Honarvar AK, Andersson S, Moslemi AR, Oldfors A, Holme E, et al. Ophthalmological findings in children and young adults with genetically verified mitochondrial disease. Br J Ophthalmol 2010; 94: 121-127.
124. Agostino A, Valletta L, Chinnery PF, Ferrari G, Carrara F, Taylor RW, et al. Mutations of ANT 1, Twinkle, and POLG1 in sporadic progressive external ophthalmoplegia (PEO). Neurology 2003; 60: 1354-1356.
125. Ksiazek SM, Peterson PL, Frank RN, Swas F. Retinopathy in non-Kearns-Sayre mitochondrial disease. Neurology 1990; 40: 312.
126. Scaglia F, Towbin JA, Craigen WJ, Belmont JW, Smith EO, Neish SR, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 2004; 114: 925-931.
127. Towbin J. Mitochondrial cardiology. In: DiMauro S, Hirano M, Schon EA (eds) Mitochondrial medicine. Informa Healthcare, Abingdon, 2006; 75-104.
128. Yaplito-Lee J, Weintraub R, Jamsen K, Chow CW, Thorburn DR, Boneh A. Cardiac manifestations in oxidative phosphorylation disorders of childhood. J Pediatr 2007; 150: 407-411.
129. Finsterer J. Histiocytoid cardiomyopathy: a mitochondrial disorder. Clin Cardiol 2008; 31: 225-227.
130. Schiff M, Ogier de Baulny H, Lombès A. Neonatal cardiomyopathies and metabolic crises due to oxidative phosphorylation defects. Semin Fetal Neonatal Med 2011; 16: 216-221.
131. Brunetti-Pierri N, Pignatelli R, Fouladi N, Towbin JA, Belmont JW, Craigen WJ, et al. Dilation of the aortic root in mitochondrial disease patients. Mol Genet Metab 2011; 103: 167-170.
132. Bennett MJ, Sherwood WG, Gibson KM, Burlina AB. Secondary inhibition of multiple NAD-requiring dehydogenases in respiratory complex I deficiency: Possible metabolic markers for the primary defect. J Inher Metab Dis 1993; 16: 560-562.
133. Hagenfeldt L. Compromised fatty acid oxidation in mitochondrial disorders. J Inher Metab Dis 1998; 21: 613-617.
134. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annual Rev Physiol 2002; 64: 477-502.
135. Axelrod FB, Chelimsky G, Weese-Mayer DE. Pediatric autonomic disorders. Pediatrics 2006; 118: 309-321.
136. Kanjwal K, Karabin B, Kanjwal Y, Saeed B, Grubb BP. Autonomic dysfunction presenting as orthostatic intolerance in patients suffering from mitochondrial cytopathy. Clin Cardiol. 2010; 33: 626-629.
137. Niaudet P, Rotig A. The kidney in mitochondrial cytopathies. Kidney Int 1997; 51: 1000-1007.
138. DiMauro S, Schon E. Mitochondrial respiratory-chain diseases. N Engl J Med 2003; 348: 2656-2668.
139. Matsutani H, Mizusawa Y, Shimoda M, Niimura F, Takeda A, et al. Partial deficiency of cytochrome c oxidase with isolated proximal renal tubular acidosis and hypercalciuria. Child Nephrol Urol 1992; 12: 221-224.
140. Wong LJ, Scaglia F, Graham BH, Craigen WJ. Current molecular diagnostic algorithm for mitochondrial disorders. Mol Genet Metab 2010; 100: 111-117.
141. Martín-Hernández E, García-Silva MT, Vara J, Campos Y, Cabello A, Muley R, et al. Renal pathology in children with mitochondrial diseases. Pediatr Nephrol 2005; 20: 1299-1305.
142. Rötig A, Appelkvist EL, Geromel V, Chretien D, Kadhom N, Edery P, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000; 356: 391-395.
143. Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 2005; 65: 606-608.
144. Amiot A, Tchikviladzé M, Joly F, Slama A, Hatem DC, Jardel C, et al. Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction. Gastroenterology 2009; 137: 101-109.